Abstract
MOLECULAR DETECTION OF TYROSINE KINASE INHIBITOR RESISTANT MUTATIONS T3151AND F317L IN CHRONIC MYELOID LEUKEMIA IN SUDAN

*Noah Awad, Aboalgasim Abaas, Nawal Altayeb and Hiba Khalil

ABSTRACT

Background and Objectives: Chronic myeloid leukemia (CML) is disease that differentiated by gene called the bcr-abl fusion gene which produced bcr-abl fusion protein. The detection of tyrosine kinase inhibitor (TKI), imatinib, enhancement the treatment of CML patients, some patients resistant to the Imatinib resulting in increased bcr-abl level. Our general objective is to determine the frequencies and prognostic value of T3151and F317L resistant mutations in Sudanese patients with chronic myeloid leukemia, the specific objectives to generate strategies for improving treatment choices and detect resistant to therapy. Methods: Across-sectional hospital base study conducted from June 2017 to October 2019 at Alneelain University, faculty of Medical Laboratory Sciences, Khartoum, Sudan. All CML patients were diagnosed Positive of Philadelphia chromosome from Hematology oncology at Radio and Isotope Center at Khartoum, Sudan after the approval of study. Patients were included both sexes, Philadelphia chromosome result, bone marrow report, clinical feature, WHO criteria for phases of disease and treatment. Results: Tow patients (2%) were found positive for both T315I mutant gene and F313L mutation and only one patient was positive for T315I mutant gene. Interpretation & conclusions: 3% positive T315I mutation and 2% positive F315L mutation are rare among the African population and very important to discover that. Screenings for bcr-abl mutations test for T315I and F317L mutations in CML patients give a good choice of specific treatment after resistant to Imatinib. We plan for future to investigate CML patients to screening tyrosine domain for other mutations before treatment as strategies.

Keywords: Allele – specific oligonucleotide polymerase chain reaction, Chronic Myeloid Leukemia, Imatinib, Myeloproliferative disease, Resistance.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation

  • EJBPS: APRIL ISSUE PUBLISHED

    APRIL 2021 Issue has been successfully launched on 1 April 2021.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT